Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates, however there is insufficient data regarding its use in patients with CKD. We evaluated SOF in patients with hepatitis C genotype 1 (G1) and moderately impaired renal function. Methods: We retrospectively reviewed all patients treated with a SOF-based regimen from December 2013 through September 2015 at Virginia Mason Medical Center. Data was then collected for HCV G1 patients with stage 3 CKD. Results: A total of 28 patients with HCV G1 and stage 3 CKD were treated with a SOF-based regimen. Twenty-one patients had stage 3A CKD (estimated glomerular filtration rate [eGFR] 45–60 mL/min/1.73m2) and 7 patients had stage 3B CKD (eGFR 30–45 mL/min/1.73m2). The overall rate of sustained virologic response (SVR) 12 weeks after completion of therapy (SVR12) was 85.7% (24/28). SVR12 in stage 3A CKD patients was 81.0% (17/21) and in stage 3B CKD patients, SVR12 was 100% (7/7). Based on the treatment regimen used, the SVR12 was 81.8% (9/11), 92.3% (12/13), and 75.0% (3/4) for SOF/ledipasvir (LDV), SOF/simeprevir (SIM), and SOF/pegylated interferon (PEG)/ribavirin (RBV), respectively. Greater than 30% reduction eGFR was observed in 4 out of 28 patients. Conclusions: SOF-based regimens resulted in high SVR12 rates in patients with moderately impaired renal function. During therapy, HCV patients with CKD should be carefully monitored for worsening renal function.
Abstract
Background/Aims: Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates, however there is insufficient data regarding its use in patients with CKD. We evaluated SOF in patients with hepatitis C genotype 1 (G1) and moderately impaired renal function. Methods: We retrospectively reviewed all patients treated with a SOF-based regimen from December 2013 through September 2015 at Virginia Mason Medical Center. Data was then collected for HCV G1 patients with stage 3 CKD. Results: A total of 28 patients with HCV G1 and stage 3 CKD were treated with a SOF-based regimen. Twenty-one patients had stage 3A CKD (estimated glomerular filtration rate [eGFR] 45–60 mL/min/1.73m2) and 7 patients had stage 3B CKD (eGFR 30–45 mL/min/1.73m2). The overall rate of sustained virologic response (SVR) 12 weeks after completion of therapy (SVR12) was 85.7% (24/28). SVR12 in stage 3A CKD patients was 81.0% (17/21) and in stage 3B CKD patients, SVR12 was 100% (7/7). Based on the treatment regimen used, the SVR12 was 81.8% (9/11), 92.3% (12/13), and 75.0% (3/4) for SOF/ledipasvir (LDV), SOF/simeprevir (SIM), and SOF/pegylated interferon (PEG)/ribavirin (RBV), respectively. Greater than 30% reduction eGFR was observed in 4 out of 28 patients. Conclusions: SOF-based regimens resulted in high SVR12 rates in patients with moderately impaired renal function. During therapy, HCV patients with CKD should be carefully monitored for worsening renal function.
참고문헌 (15)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Shepard CW, "Global epidemiology of hepatitis C virus infection", Lancet Infect Dis, 5, pp.558~567 (2005)
- 손혜석, "Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012", Clinical and Molecular Hepatology, 21(3), pp.249~256 (2015), 대한간학회
- Saxena V., "Safety and efficacy of sofosbuvir-containing regimens in hepatitis Cinfected patients with impaired renal function", Liver Int, 36, pp.807~816 (2016)
- Park H, "A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection", J Viral Hepat, 22, pp.897~905 (2015)
- Berenguer M, "Treatment of chronic hepatitis C in hemodialysis patients", Hepatology, 48, pp.1690~1699 (2008)
- Bunchorntavakul C, "Management of patients with hepatitis C infection and renal disease", World J Hepatol, 7, pp.213~225 (2015)
- Smolders EJ, "Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and", or renal impairment, 2016, pp.39, 589~611
- Levey AS, "A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation", Ann Intern Med, 130, pp.461~470 (1999)
- Zeuzem S, "Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a", ribavirin, 2012, pp.19, 766~774
- Vardeny O, "Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)", J Am Coll Cardiol, 60, pp.2082~2089 (2012)
- Cornprost M, "The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977", J Hepatol, 56, pp.S433~ (2012)
- Bhamidimarri KR, "Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease", J Hepatol, 63, pp.763~765 (2015)
- Nazario HE, "Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR < 30 ml", min, 2016, pp.36, 798~801
- Canonico PG, "Effects of ribavirin on red blood cells", Toxicol Appl Pharmacol, 74, pp.155~162 (1984)